In 2020, Sue volunteered for a study at the Washington University School of Medicine in St. Louis. Researchers there were ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after ... regulatory standards for this medicine have been met." The approval is contingent ...

Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband isn't sure if it made a difference.

In 2020, Sue volunteered for a study at the Washington University School of Medicine in St. Louis. Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by ...